Physician profile
Erin D Roe
NPI 1174726590
$11,032.24
in general payments reported to CMS, 2019-2025
49 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,120 · 2020: $4,180 · 2021: $1,963 · 2022: $1,241 · 2023: $728 · 2024: $310 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.12 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $3,200.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,349.24 | 2019-2022 | |
| Novo Nordisk INC | $1,176.93 | 2019-2022 | |
| Lilly USA, LLC | $908.47 | 2019-2025 | Jardiance, Lyumjev, Baqsimi |
| Mannkind Corporation | $619.88 | 2019-2025 | Afrezza |
| Amgen INC. | $452.13 | 2019-2025 | Tepezza |
| Dexcom, INC. | $341.14 | 2019-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $309.61 | 2019-2022 | |
| Abbvie INC. | $269.20 | 2019-2023 | Synthroid |
| Insulet Corporation | $244.77 | 2019-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.29 | 2019-2022 | |
| Medtronic Minimed, INC. | $178.77 | 2019-2020 | |
| Radius Health, INC. | $171.45 | 2019-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $153.61 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $151.80 | 2019-2025 | Strensiq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.